Tecentriq combo first I-O regimen to get approval in breast cancer

Roche’s (ROG: SIX) PD-L1 inhibitor Tecentriq (atezolizumab) has shown again that it is not so far behind immuno-oncology’s frontrunners.

It has been approved by the US Food and Drug Administration (FDA), in combination with the chemotherapy drug Abraxane (paclitaxel protein-bound particles for injectable suspension) for unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, as determined by an FDA-approved test.

This indication is approved under accelerated approval based on progression-free survival, and makes the Tecentriq combination the first cancer immunotherapy (I-O) regimen to be approved for breast cancer in the USA.